Ostarine: Dose Dependent Results

Conclusion: Dose Dependent Results for Ostarine with limited reported side effects that can be attributed to this compound. Trials include both men and women, and its intended use is in SUI for women, so we can assume this is safe for both genders. It’s not yet clear to me up to what point dose dependent results can be achieved - I'd speculate that the broscience of 20-30mg is probably about right but will seek to confirm this in coming months with study data.

Enobosarm, aka Ostarine, GTx-024, has been in human trials for some time, with the intent for it to be a solution of Stress Urinary Incontinence (http://www.gtxinc.com/science/selective-androgen-receptor-modulator-sarm/sarms-in-urology/) but with a number of other potential label uses also being examined including in muscle related diseases/disorders (https://academic.oup.com/hmg/article-abstract/doi/10.1093/hmg/ddx150/3770516/Androgen-Receptor-Agonists-Increase-Lean-Mass?redirectedFrom=fulltext; https://clinicaltrials.gov/ct2/show/NCT01355484).

With the advancement of studies involving GTx-024, the evaluation for potential uses of the drug are increasingly specific. Therefore, to find a study that looks at general health, safety and efficacy without being specific to a certain use I am referring to a 2011 phase II trial for my data. That said, across all recent studies, no significant side effects have been reported that I can trace back to the use of GTx-024 and a Phase II 2018 announcement stating: ‘1200 subjects were treated with enobosarm at doses ranging from 0.1 mg to 100 mg. At all evaluated dose levels, enobosarm was observed to be generally safe and well tolerated’: https://www.businesswire.com/news/home/20180222006442/en/GTx-Phase-2-Enobosarm-Clinical-Trial-Results. I would love to see the results at 100mg but can't find this anywhere else and might be an overzealous marketing manager making an unsubstantiated claim.

Firstly, the mean age was 63.3, obviously not an amazing target audience for our purposes. But what is useful for us is the dose dependent relationship in LBM% gain to dose – 1% at 1mg, 3% at 3mg: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3177038/figure/Fig1/. Notably, blood glucose, blood insulin, and insulin resistance were all reduced.

This 2011 study draws some interesting conclusions from the data stating that ‘In men, no statistically significant differences from placebo in change from baseline values for free testosterone, DHT, estradiol, follicle-stimulating hormone (FSH), or LH were observed at any GTx-024 dose (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3177038/). However I will respectfully disagree and ask you to look for yourself: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3177038/table/Tab5/. Free test, total test and SHBG fell significantly, as did LH which was the likely cause of the decrease in test. FSH was only slightly reduced. What is extremely interesting for PED users is that estradiol also fell significantly. When we think of the causes of gyno, we think of a few actions with one being estradiol remaining high while test falls in a SARM only cycle (https://www.reddit.com/r/PEDsR/comments/85ycd0/what_is_the_root_cause_of_gynecomastia_potential/).

Issues with this analysis – I make the claim results are dose dependent, but do not qualify to what point. Studies involving higher doses of 10mg-100mg are not readily available without getting behind a paywall. Accordingly, I will update this as I get more studies released to the public, probably in July 2018 which is when the next study results is due to be released. Or not – GTx seems to know they have a winner here and I’m not seeing a lot of published results other than those completed years ago, PR articles, or just an announcements relating to the completion but no study to view.